Pharmaceutical In response to the government of India’s constitution of Standing Committee on Affordable Medicines and Health Products (SCAMHP) issued last month, Prashant Khadayate, pharma analyst at GlobalData, comments: “This seems to be an extension of the Indian government’s objective to make drugs more affordable, especially for drugs not in the purview of price control. Previously, the Directorate General of Health Services (DGHS) had recommended to cap the trade margins on a list of 50 drugs, including 39 drugs being used in treatment of cancer and rare diseases. 7 February 2019